Published: 11 July 2022
Author(s): Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
Section: Letter to the Editor

Potent antiviral therapy (AVT) against hepatitis B virus (HBV) can induce regression of liver fibrosis, thereby reducing the development of liver cirrhosis and hepatocellular carcinoma (HCC) [1]. A high recurrence rate even after curative surgical resection of HCC remains a major challenge [2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.